Guggenheim analyst Subbu Nambi initiated coverage of 10x Genomics with a Buy rating and $60 price target. The analyst initiated coverage on nine select specialty tools and specialty diagnostic lab companies. The life sciences tools group remains a large and growing industry where innovation expands applications and opens up new markets, the analyst tells investors in a research note. The firm says that over time, these applications can enable the development of disruptive therapies. Guggenheim’s top picks are Illumina (ILMN), Natera (NTRA) and Exact Sciences (EXAS).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- Wolfe starts 10x Genomics at Outperform, cites ‘scarcity value’ of profile
- 10x Genomics just upgraded at BofA, here’s why
- 10x Genomics collaborates with NIH CARD on neuroscience research
- Curio Bioscience to ‘vigorously defend’ against 10x Genomics’ allegations
- NanoString downgraded to Neutral from Overweight at JPMorgan
